Physicians are discussing top-line results from the phase III Krascendo 1 trial, where the next-generation KRAS G12C inhibitor divarasib showed superiority over first-generation agents with improved PFS and OS in second-line NSCLC. Another topic is a SEER-Medicare analysis highlighting that less than half of older adults (≥65 years) with metastatic NSCLC received systemic therapy.
“Top-line results from randomized phase III Krascendo 1 trial shows divarasib superior to first generation KRAS G12C inhibitors with improved PFS and significant improvement in OS, meeting primary endpoint.”
— @StephenVLiu · Divarasib in Krascendo 1 · View post ↗
“Significant press release from KRASCENDO-1 trial showing that novel KRAS inhibitor divarasib significantly improves both PFS and OS compared to approved agents sotorasib and adagrasib in patients with KRAS G12C mut NSCLC”
— @g_mountzios · Divarasib vs. sotorasib/adagrasib · View post ↗📌 Amplified by @KolPulseAI
“only 46.8% of patients ≥65 years ever received systemic therapy, with minimal improvement from 2006 to 2021.”
— @diegoadiazg · Treatment gaps in older adults · View post ↗Physicians are discussing interim analysis from the phase 3 HORIZON-Breast01 trial, where the ADC trastuzumab rezetecan demonstrated a PFS benefit versus pyrotinib plus capecitabine in previously treated HER2+ metastatic breast cancer. Another topic is the use of FES (fluoroestradiol) PET scans, which use a radiolabeled estradiol tracer to visualize ER+ breast cancer.
“In the interim analysis of HORIZON-Breast01, trastuzumab rezetecan delivered a striking PFS benefit over pyrotinib + capecitabine in previously treated HER2+ metastatic breast cancer.”
— @DrRishabhOnco · HORIZON-Breast01 Results · View post ↗
“Radiolabeled estradiol is used as the tracer and it binds to the estrogen receptor (ER), allowing for visualization of ER+ breast cancer.”
— @allisonoconn · FES PET Scans · View post ↗
“Optimizing Cancer Care Delivery Through High-Functioning Teams: Results of Implementing the 4R Oncology Model in Lung and Breast Cancers”
— @mirrorsmed · 4R Oncology Model · View post ↗Physicians are discussing data from ESMO GI, including results from the EMERALD-1 and EMERALD-3 trials evaluating combinations with TACE in HCC. For pancreatic cancer, early data on the KRAS G12D inhibitor zoldonrasib and on daraxonrasib is being shared, with notable response rates for zoldonrasib plus chemotherapy. Additionally, the recent FDA approval of zenocutuzumab for NRG1-fusion positive cholangiocarcinoma is a key topic.
“🔹 Zenocutuzumab is now FDA-approved for NRG1-fusion positive cholangio”
— @JamesClearyMD · Zenocutuzumab approval · View post ↗
“🥳ORR 82% mFOLFIINOX; 61% GN”
— @DrAngelaLamarca · Zoldonrasib in PDAC · View post ↗
“👉OR & PFS improved 👉no OS benefit”
— @ArndtVogel · EMERALD-1 in HCC · View post ↗Physicians are discussing new publications on HIF-2α inhibitors in clear-cell renal cell carcinoma (ccRCC). The LITESPARK-022 trial showed adding belzutifan to adjuvant pembrolizumab improved DFS (HR 0.72) but increased Grade ≥3 adverse events. In prostate cancer, the ARTO trial demonstrated an overall survival benefit (HR 0.55) by adding SBRT to abiraterone and ADT for oligometastatic CRPC.
“24-month DFS: 80.7% vs 73.7% (HR 0.72; P<0.001). OS not yet significant at interim.”
— @drenriquegrande · LITESPARK-022 results · View post ↗
“In oligometCRPC, adding SBRT to abi+ADT significantly improves Overall Survival (HR 0.55, p=0.021).”
— @PietroGarlatti · ARTO trial results · View post ↗
“This trial evaluated the HIF-2α inhibitor Casdatifan in heavily pretreated advanced ccRCC and provides important insights into HIF-2α biology and response.”
— @DrChoueiri · ARC-20 trial · View post ↗📌 Amplified by @KolPulseAI
Physician discussion centers on sequencing advanced therapies, particularly the comparison of CAR-T versus bispecifics after the failure of an initial BCMA-targeted therapy. Other topics include the final analysis of the DREAMM-9 trial, which evaluated Blenrep plus VRd in newly diagnosed patients, and a new preclinical strategy involving a selective IRF4 degrader.
“CAR-T vs Bispecifics — Which Performs Better in #Myeloma After Initial BCMA Therapy Fails?”
— @MyelomaTeacher · Treatment Sequencing · View post ↗📌 Amplified by @KolPulseAI
“DREAMM-9 Final Analysis: Blenrep + VRd Shows Lasting Benefit in Newly Diagnosed #Myeloma”
— @MyelomaTeacher · DREAMM-9 Trial · View post ↗
“In a @nchembio study, @DanaFarber researchers report the first selective IRF4 degrader, a promising preclinical strategy against multiple myeloma.”
— @DanaFarberNews · Preclinical Research · View post ↗Physicians are discussing final results from the Phase 3 TRANSFORM-1 trial, where adding navitoclax to ruxolitinib improved spleen responses in JAK inhibitor-naïve myelofibrosis. Other key topics include positive Phase 3 results for BRUKINSA in frontline Mantle Cell Lymphoma and a Phase 1/2 study of sonrotoclax in relapsed/refractory MCL.
“Proud to share our international randomized frontline Myelofibrosis Ph3 #TRANSFORM-1 final results | #Navitoclax + RUXO”
— @doctorpemm · TRANSFORM-1 trial · View post ↗
“Phase 3 TRANSFORM-1: Adding navitoclax to ruxolitinib improved spleen responses in JAK inhibitor–naïve intermediate-2/high-risk myelofibrosis.”
— @MostafaFaisal14 · TRANSFORM-1 results · View post ↗
“BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma”
— @tobyeyre82 · BRUKINSA in MCL · View post ↗📌 Amplified by @KolPulseAI